Evidence mapPaperPMID 39680410Full record

ArticleJAMA network open2024

Coronary Microvascular Dysfunction Years After Cessation of Anabolic Androgenic Steroid Use.

Yeliz Bulut, Jon Jarløv Rasmussen, Niels Brandt-Jacobsen, Jan Frystyk, Mario Thevis, Morten Schou, Finn Gustafsson, Philip Hasbak, Caroline Kistorp

Abstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yeliz BulutDepartment of Nephrology and Endocrinology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Jon Jarløv RasmussenDepartment of Nephrology and Endocrinology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Niels Brandt-JacobsenDepartment of Nephrology and Endocrinology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Jan FrystykDepartment of Endocrinology, Odense University Hospital, Odense, Denmark.
Mario ThevisCenter for Preventive Doping Research, German Sport University, Cologne, Germany.
Morten SchouDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Denmark, Copenhagen, Denmark.
Finn GustafssonDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Denmark, Copenhagen, Denmark.
Philip HasbakDepartment of Clinical Physiology and Nuclear Medicine, and Cluster for Molecular Imaging, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Caroline KistorpDepartment of Nephrology and Endocrinology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Long-term use of anabolic androgenic steroids (AASs) is associated with a high risk of left ventricular hypertrophy, heart failure with reduced systolic function, and early sudden death, with the mechanism of progression being understudied. Early and persistent impaired myocardial microcirculation could be of clinical importance and a potential underlying mechanism of frequent and early cardiac disease among individuals with AAS use and a future potential target for intervention. Objective: To investigate coronary microcirculation by measuring myocardial flow reserve (MFR) in men with current and former AAS use compared with controls with no prior AAS use, using cardiac rubidium 82 (82Rb) positron emission tomography/computed tomography (PET/CT). Design, Setting, and Participants: This cross-sectional study included men involved in recreational strength training without established cardiovascular disease grouped according to their history of AAS use. The study was conducted November 24, 2021, to August 16, 2023. Exposure: Cardiac PET/CT with 82Rb was performed at rest and after adenosine-induced stress. Main Outcome and Measure: The primary outcome of this study was the MFR among the study groups; a secondary outcome was the coronary calcium score. By definition, impaired myocardial microcirculation was determined using a cutoff of MFR less than 2, and subclinically impaired microcirculation was determined using a cutoff of MFR less than 2.5. Results: A total of 90 men (32 with current AAS use, 31 with former AAS use, and 27 controls) were included. Mean (SD) age was 35.1 (8.7) years. Elapsed duration since AAS cessation was a geometric mean of 1.5 (95% CI, 0.9-2.5) years. Eighteen men (58.1%) with former use discontinued AAS use more than 1 year before enrollment. Impaired MFR was present in those with current (6 [18.8%]) and former (1 [3.2%]) use, whereas no impairment was observed among the controls (P = .02). Subclinically impaired MFR was higher among men with current (9 [28.1%]) and former (8 [25.8%]) AAS use than the controls (1 [3.7%]) (P = .02). In a multivariable logistic regression model among men with former AAS use, every doubling of the accumulated weekly duration of AAS use (log2) was independently associated with a factor 2 increase in the risk of impaired MFR less than 2.5 (odds ratio, 2.1; 95% CI, 1.03-4.35; P = .04). Conclusions and Relevance: In this study, men with former AAS use displayed impaired MFR years after AAS cessation, suggesting impaired coronary microcirculation persists beyond active use.

Indexed as

MicrocirculationPositron Emission Tomography Computed TomographyAdultAnabolic AgentsAnabolic Androgenic SteroidsCoronary CirculationCross-Sectional StudiesHumansMaleMiddle AgedTestosterone CongenersAnabolic AgentsAnabolic Androgenic SteroidsTestosterone Congeners

Identifiers

PMID39680410
PMCPMC11650407

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.